全文获取类型
收费全文 | 45829篇 |
免费 | 3488篇 |
国内免费 | 180篇 |
专业分类
耳鼻咽喉 | 372篇 |
儿科学 | 1498篇 |
妇产科学 | 1198篇 |
基础医学 | 6550篇 |
口腔科学 | 587篇 |
临床医学 | 4954篇 |
内科学 | 9499篇 |
皮肤病学 | 874篇 |
神经病学 | 5505篇 |
特种医学 | 1114篇 |
外科学 | 4127篇 |
综合类 | 377篇 |
一般理论 | 58篇 |
预防医学 | 5465篇 |
眼科学 | 607篇 |
药学 | 2939篇 |
中国医学 | 85篇 |
肿瘤学 | 3688篇 |
出版年
2024年 | 41篇 |
2023年 | 599篇 |
2022年 | 462篇 |
2021年 | 2134篇 |
2020年 | 1297篇 |
2019年 | 1772篇 |
2018年 | 2033篇 |
2017年 | 1361篇 |
2016年 | 1512篇 |
2015年 | 1659篇 |
2014年 | 2024篇 |
2013年 | 2621篇 |
2012年 | 4194篇 |
2011年 | 4149篇 |
2010年 | 2103篇 |
2009年 | 1844篇 |
2008年 | 2942篇 |
2007年 | 2905篇 |
2006年 | 2773篇 |
2005年 | 2568篇 |
2004年 | 2277篇 |
2003年 | 2034篇 |
2002年 | 1731篇 |
2001年 | 192篇 |
2000年 | 142篇 |
1999年 | 207篇 |
1998年 | 347篇 |
1997年 | 260篇 |
1996年 | 212篇 |
1995年 | 175篇 |
1994年 | 123篇 |
1993年 | 117篇 |
1992年 | 64篇 |
1991年 | 65篇 |
1990年 | 54篇 |
1989年 | 56篇 |
1988年 | 48篇 |
1987年 | 36篇 |
1986年 | 35篇 |
1985年 | 33篇 |
1984年 | 45篇 |
1983年 | 43篇 |
1982年 | 32篇 |
1981年 | 39篇 |
1980年 | 28篇 |
1979年 | 17篇 |
1978年 | 13篇 |
1977年 | 20篇 |
1975年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
Alessandra Elvevi Elena Maria Elli Martina Luc Miki Scaravaglio Fabio Pagni Stefano Ceola Laura Ratti Pietro Invernizzi Sara Massironi 《World journal of gastroenterology : WJG》2022,28(29):3767-3779
Mastocytosis is a rare and heterogeneous disease characterized by various clinical and biological features that affect different prognoses and treatments. The disease is usually divided into 2 principal categories: cutaneous and systemic disease (SM). Clinical features can be related to mast cell (MC) mediator release or pathological MC infiltration. SM is a disease often hard to identify, and the diagnosis is based on clinical, biological, histological, and molecular criteria with different specialists involved in the patient’s clinical work-up. Among all manifestations of the disease, gastrointestinal (GI) symptoms are common, being present in 14%-85% of patients, and can significantly impair the quality of life. Here we review the data regarding GI involvement in SM, in terms of clinical presentations, histological and endoscopic features, the pathogenesis of GI symptoms, and their treatment. 相似文献
992.
Valerio Rosato Antonio Ascione Riccardo Nevola Anna Ludovica Fracanzani Guido Piai Vincenzo Messina Ernesto Claar Carmine Coppola Luca Fontanella Rosa Lombardi Laura Staiano Giovanna Valente Maria Chiara Fascione Chiara Giorgione Annalisa Mazzocca Raffaele Galiero Pasquale Perillo Aldo Marrone Ferdinando Carlo Sasso Luigi Elio Adinolfi Luca Rinaldi 《Journal of viral hepatitis》2022,29(1):26-34
The long-term changes of liver stiffness (LS) in patients who achieve viral clearance after direct-acting anti-HCV therapy remain undefined. We conducted a multicentre prospective study to investigate this aspect. Patients with HCV infection treated with DAAs were enrolled from six Italian centres; they underwent clinical, biochemical, ultrasound and transient elastography evaluations before treatment (T0), 12 weeks (SVR12) and 24 months (T24) after the end of therapy. Among the 516 consecutive patients enrolled, 301 had cirrhosis. LS significantly decreased from T0 to SVR (14.3 vs 11.1 kPa, p = .002), with a progressive reduction until T24 (8.7 kPa, p < .001). However, only patients with steatosis and those who developed HCC did not experience a late improvement in LS. Multivariate analysis of baseline and follow-up variables identified steatosis as the only independent predictor of failure of LS improvement (OR 1.802, p = .013). ROC curve analysis of the association of LS with the risk of developing HCC showed that SVR12 ≥14.0 kPa had the highest accuracy (sensitivity 82%, specificity 99%; AUC: 0.774). Multivariate analysis revealed that LS was the only variable independently associated with an increased risk of developing HCC (OR 6.470, p = .035). Achieving an SVR was associated with a progressive, long-term decline of LS, suggesting a late improvement in liver fibrosis, besides the resolution of inflammation. Fatty liver and the development of HCC interfered with late reduction of LS. Patients with an LS ≥14 kPa at 12 weeks after the end of treatment were at higher risk for developing HCC. 相似文献
993.
Johnson Laura M. Green Harold D. Lu Minggen Stockman Jamila K. Felsher Marisa Roth Alexis M. Wagner Karla D. 《AIDS and behavior》2022,26(9):2866-2880
AIDS and Behavior - Pre-Exposure Prophylaxis (PrEP) health campaigns invite women to talk with their provider, partner, and peers about PrEP, though they do not offer specific guidance about who... 相似文献
994.
Adriana Ahumada Laura Ray n Clara Us n Rafael Ba ares Sonia Alonso Lopez 《World journal of gastroenterology : WJG》2021,27(40):6737-6749
Hepatitis C virus (HCV) chronic infection is associated with fibrosis progression, end-stage liver complications and HCC. Not surprisingly, HCV infection is a leading cause of liver-related morbidity and mortality worldwide. After sustained virological response (SVR), the risk of developing hepatocellular carcinoma is not completely eliminated in patients with established cirrhosis or with advanced fibrosis. Therefore, lifelong surveillance is currently recommended. This strategy is likely not universally cost-effective and harmless, considering that not all patients with advanced fibrosis have the same risk of developing HCC. Factors related to the severity of liver disease and its potential to improve after SVR, the molecular and epigenetic changes that occur during infection and other associated comorbidities might account for different risk levels and are likely essential for identifying patients who would benefit from screening programs after SVR. Efforts to develop predictive models and risk calculators, biomarkers and genetic panels and even deep learning models to estimate the individual risk of HCC have been made in the direct-acting antiviral agents era, when thousands of patients with advanced fibrosis and cirrhosis have reached SVR. These tools could help to identify patients with very low HCC risk in whom surveillance might not be justified. In this review, factors affecting the probability of HCC development after SVR, the benefits and risks of surveillance, suggested strategies to estimate individualized HCC risk and the current evidence to recommend lifelong surveillance are discussed. 相似文献
995.
996.
Kane Jeremy C. Sharma Anjali Murray Laura K. Chander Geetanjali Kanguya Tukiya Skavenski Stephanie Chitambi Chipo Lasater Molly E. Paul Ravi Cropsey Karen Inoue Sachi Bosomprah Samuel Danielson Carla Kmett Chipungu Jenala Simenda Francis Vinikoor Michael J. 《AIDS and behavior》2022,26(2):523-536
AIDS and Behavior - This randomized controlled trial tested the efficacy of a multi-session, evidence-based, lay counselor-delivered transdiagnostic therapy, the Common Elements Treatment Approach... 相似文献
997.
Laura Di Domenico Chiara E Sabbatini Giulia Pullano Daniel Lvy-Bruhl Vittoria Colizza 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2021,26(15)
Following the spread of the SARS-CoV-2 B.1.1.7 variant, social distancing was strengthened in France in January 2021. Using a two-strain mathematical model calibrated on genomic surveillance, we estimated that curfew measures allowed hospitalisations to plateau by decreasing transmission of the historical strains while B.1.1.7 continued to grow. School holidays appear to have further slowed down progression in February. Without progressively strengthened social distancing, a rapid surge of hospitalisations is expected, despite the foreseen increase in vaccination rhythm. 相似文献
998.
Lauren L. O'Mahoney PhD Patrick J. Highton PhD Laura Kudlek MSc Jessica Morgan BA Rosie Lynch BA Ella Schofield BMBCh Nayanika Sreejith BA Ajay Kapur BMBCh Afolarin Otunla BA Sven Kerneis BMBCh Olivia James BA Karen Rees PhD Ffion Curtis PhD Kamlesh Khunti FMedSci Jamie Hartmann-Boyce DPhil 《Diabetes, obesity & metabolism》2022,24(9):1850-1860
999.
1000.
Francesco Vendrame Peter Calhoun Laura E. Bocchino Richard E. Pratley Anna Casu 《Journal of diabetes and its complications》2021,35(6):107884
AimTo investigate the impact of bariatric surgery and weight loss medications in adults with type 1 diabetes.Materials and methodsSubjects enrolled in the T1D Exchange (T1DX) Clinic Registry age ≥ 18 years with a diabetes duration of ≥1 year were included in the analysis (n = 13,501). Data for participants (n = 37) with bariatric surgery after diabetes onset were assessed before and after surgery and also compared to a matched control group. Data for participants who reported the use of FDA-approved weight loss medications (n = 483) were assessed before starting, during use, and after stopping the medications and also compared to a matched control group. Variables of interest included BMI, HbA1c, blood pressure, lipid profile, rates of acute complications. Data were analyzed using linear mixed models.ResultsBariatric surgery resulted in BMI reduction from 38.8 ± 9.1 kg/m2 to 33.3 ± 6.7 kg/m2 (P = 0.006) and HbA1c reduction from 8.8 ± 1.3% (73 ± 14.2 mmol/mol) to 8.1 ± 1.1% (65 ± 12.0 mmol/mol) (P = 0.05). Weight loss medications were not associated with weight loss or better glycemic control although stopping liraglutide favored weight gain. Both interventions were not associated with a significant change in blood pressure or lipid profile. There were no adverse events associated with the use of weight loss medications.ConclusionsBariatric surgery is effective for weight loss and may improve glycemic control in selected patients. Weight loss medications are not associated with diabetes improvement. A trial with liraglutide may be attempted for weight control, but weight loss medications in general do not show a significant effect. 相似文献